$BCDA

BioCardia, Inc.

BioCardia develops regenerative therapies for cardiovascular and pulmonary diseases. Its candidates include CardiAMP, a therapy using a patient’s own cells for ischemic heart failure and refractory angina, and CardiALLO, a donor cell therapy for ischemic heart failure. PulmALLO targets acute respiratory distress syndrome. BioCardia also offers the Helix system for targeted delivery of biologic agents to the heart, Heart3D fusion imaging, and morph DNA and avance steerable introducers. The company is based in Sunnyvale, California.

AlphAI earnings readQ3 FY2026 · NOV 12BioCardia Q3 2026: net loss of $(1,817) thousand, cash of $2,224 thousand, company cites runway into 2027Verdict: weak

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
1
2

No SEC Form 4 filings for $BCDA in the last 30 days.

See all $BCDA insider activity →
Med

BioCardia’s heart failure cell therapy moves closer in Japan

BioCardia, a regenerative medicine company, is advancing its CardiAMP cell therapy for ischemic heart failure in Japan. The treatment uses a patient's own cells and is delivered via catheter. BioCardia's technology includes precision medicine and proprietary delivery systems.

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

BioCardia Reports Q3 2026 Net Loss of $1.8 Million

BioCardia reported a Q3 2026 net loss of $1.8M, up from $1.5M a year earlier. Cash reserves were $2.2M, with $1.7M used in operations. The company made progress on CardiAMP, Helix, and Heart3D programs, with key regulatory milestones expected in 2027.

BCDA sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BCDA (BioCardia, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 2 bearish.

Recent BCDA coverage spans earnings, regulation and technology.

What's driving BCDA

  • BioCardia, a regenerative medicine company, is advancing its CardiAMP cell therapy for ischemic heart failure in Japan. The treatment uses a patient's own cells and is delivered via catheter. BioCardia's technology includes precision medicine and proprietary delivery systems.

    longevity.technology · Nov 18, 2026

  • Earnings beat expectations with modest loss; regulatory milestones could drive future upside.

    finance.yahoo.com · Nov 13, 2026

  • The loss and low cash balance suggest near‑term financing pressure.

    tradingview.com · Nov 12, 2026

  • The quarterly loss and limited cash runway create near‑term downside pressure, while FDA/PMDA progress on CardiAMP and Helix could spark upside if approvals materialize.

    SEC EDGAR 8-K · Nov 12, 2026

  • Analyst estimate suggests a modest loss; market may price in downside risk ahead of the actual results.

    tradingview.com · Nov 11, 2026

AlphAI scores every news story that mentions BCDA with an AI model for sentiment and relevance, and aggregates insider trades from BioCardia, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BCDA

Score

BioCardia Inc (BCDA) (Q3 2026) Earnings Call Highlights: Japan Shonin Submission Advances

BioCardia Inc (BCDA) reported Q3 2026 earnings, highlighting progress in Japan's Shonin submission for CardiAMP Cell Therapy, expected within months. CEO Peter Altman discussed partnerships, regulatory pathways, and clinical trial updates. The company reported $1.7M in net cash used in operations, with $2.2M in cash reserves. Key catalysts include FDA feedback on the Helix catheter system and potential gene therapy partnerships.

$BCDAMedEarnings

BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results Sunnyvale, Calif. – November 12, 2026 - BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases

$BCDAMedAI 8/10

BioCardia’s CardiAMP Completes Japan Pre-Market Consultation, First Cardiac Cell Therapy to Do So

BioCardia (BCDA) completed Japan's PMDA consultation for its CardiAMP Cell Therapy System, positioning it for a marketing approval application. The therapy, which uses a patient's own bone marrow cells, aims to treat heart damage. BioCardia targets a formal submission by late 2026 and commercial revenue by 2028. The company's Phase 3 trial showed significant improvements in a subgroup of patients with elevated NTproBNP levels, which PMDA has reviewed positively.

$BCDAMedClinical / regulatory

BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application SUNNYVALE, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. (NASDAQ: BCDA) , a global le

$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

$BCDAHighAI 8/10Clinical / regulatory· NDA submission

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

Related tickers